维泊妥珠单抗用于大B细胞淋巴瘤患者CAR-T细胞治疗后:一项多中心回顾性研究
这项多中心回顾性分析纳入57例CAR-T细胞治疗后复发或进展的大B细胞淋巴瘤患者,评估维泊妥珠单抗联合或不联合利妥昔单抗和苯达莫司汀的疗效。结果显示25例(44%)患者达到缓解,其中8例(14%)完全缓解,中位无进展生存期为10周(95%CI 5-15),骨髓受累和乳酸脱氢酶升高与更短的无进展生存期相关。
要点
- CAR-T治疗后复发或进展的大B细胞淋巴瘤患者接受维泊妥珠单抗治疗,缓解率为44%,完全缓解率14%。
- 中位无进展生存期仅10周,81%患者在随访期间出现疾病进展或死亡。
- 骨髓受累(HR 5.2)和乳酸脱氢酶升高(HR 5.0)与更短的无进展生存期独立相关。
核心结论
- 维泊妥珠单抗为基础的方案在CAR-T细胞治疗后复发或进展的大B细胞淋巴瘤患者中可产生缓解,但无进展生存期较短。
- 需要开展研究以更好地描述耐药的内在机制并确定这些患者的最佳巩固策略。
研究设计与样本
- 多中心回顾性分析,纳入2019年7月至2021年5月间CAR-T细胞治疗后复发或进展并接受维泊妥珠单抗联合或不联合利妥昔单抗和苯达莫司汀的大B细胞淋巴瘤患者。
- 共纳入57例患者,其中18例(32%)对CAR-T细胞治疗原发难治,34例(60%)在CAR-T细胞治疗后立即接受维泊妥珠单抗为基础的治疗。
- 54例(95%)患者联合利妥昔单抗,35例(61%)患者联合苯达莫司汀。
- 疗效评估基于2014年Lugano标准。
主要发现
- 25例(44%)患者达到缓解,其中8例(14%)完全缓解。
- 未观察到基线特征与缓解之间存在显著关联。
- 中位随访47周(95%CI 40-54)后,46例(81%)患者出现疾病进展或死亡,中位无进展生存期为10周(95%CI 5-15)。
- 多因素分析显示,骨髓受累(HR 5.2;95%CI 1.8-15;P=0.003)和乳酸脱氢酶升高(HR 5.0;95%CI 1.4-16;P=0.01)与更短的无进展生存期相关。
关键数值与推荐
- 缓解评估采用2014年Lugano标准。
- 缓解定义为达到缓解(部分缓解或完全缓解),共25例(44%);完全缓解8例(14%)。
- 中位无进展生存期为10周(95%CI 5-15)。
- 骨髓受累的HR为5.2(95%CI 1.8-15;P=0.003),乳酸脱氢酶升高的HR为5.0(95%CI 1.4-16;P=0.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polatuzumab vedotin (PV) is an antibody-drug conjugate targeting CD79b that is approved for patients with relapsed/refractory large B-cell lymphoma (LBCL). Patients who relapse after chimeric antigen receptor (CAR) T-cell therapy were not included in the registration study, and reports of PV use after CAR T cells are limited. This multicenter retrospective analysis included patients with LBCL who relapsed or progressed after CAR T-cell therapy and subsequently received PV with or without rituximab and bendamustine between July 2019 and May 2021. Response to treatment and progression were assessed based on the 2014 Lugano criteria. Fifty-seven patients were included in the study: 18 (32%) patients were primary refractory to CAR T-cell therapy, and 34 (60%) patients received PV-based therapy immediately after CAR T-cell therapy. PV was combined with rituximab in 54 (95%) patients and administered with bendamustine in 35 (61%) patients. A response was achieved in 25 (44%) patients, including complete remission in 8 (14%). No significant association between baseline characteristics and response was observed. After a median follow-up of 47 weeks (95% confidence interval [CI], 40-54), 46 (81%) patients had disease progression or died, and the median progression-free survival was 10 weeks (95% CI, 5-15). On a multivariate analysis, bone marrow involvement (hazard ratio, 5.2; 95% CI, 1.8-15; P = .003) and elevated lactate dehydrogenase levels (hazard ratio, 5.0; 95% CI, 1.4-16; P = .01) were associated with shorter progression-free survival. Studies aimed at better characterizing the intrinsic mechanism of resistance and identifying optimal consolidation strategies for these patients are warranted.
引用
- Gouni S, Rosenthal AC, Crombie JL, et al. A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. Blood Adv. 2022. PMID: 35240681. doi:10.1182/bloodadvances.2021006801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。